title: [Gastrointestinal perforation induced by bevacizumab treatment in cervix carcinoma].
authors.affiliation: Servicio de Farmacia. Hospital Germans Trias i Pujol. Badalona, Barcelona.. elisanp@hotmail.com.
authors.forename: Elisabet
authors.initials: E
authors.lastname: Nogué-Pujadas
authors.affiliation: Unidad Farmacia Oncológica. Instititut Català Oncologia. Hospital Germans Trias i Pujol. Badalona, Barcelona.. claralez@hotmail.com.
authors.forename: Clara
authors.initials: C
authors.lastname: Lezcano-Rubio
authors.affiliation: Unidad Farmacia Oncológica. Instititut Català Oncologia. Hospital Germans Trias i Pujol. Badalona, Barcelona.. dlopez@iconcologia.net.
authors.forename: David
authors.initials: D
authors.lastname: López-Sisamón
authors.affiliation: Servicio de Oncología Médica. Instititut Català Oncologia. Hospital Germans Trias i Pujol.. mromeo@iconcologia.net.
authors.forename: Margarita
authors.initials: M
authors.lastname: Romeo-Marín
mesh_terms: D020533:Angiogenesis Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D000068258:Bevacizumab / Q000009:adverse effects* / Q000627:therapeutic use; D003125:Colostomy; D005260:Female; D006801:Humans; D007416:Intestinal Perforation / Q000139:chemically induced* / Q000601:surgery; D008875:Middle Aged; D013272:Stomach Diseases / Q000139:chemically induced* / Q000601:surgery; D002583:Uterine Cervical Neoplasms / Q000150:complications* / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab